Cash flow is moderate; income statement and balance sheet are weak.
Next earnings: 2026-10-29 (BMO), EPS Forecast: $0.51
Rated Sell for the last 12 quarters. This quarter: -0.0.
Change vs previous quarter.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.